Bank of America is spending more than $250 million each year to provide GLP-1 medications to its workforce, marking a substantial shift in corporate health benefits. These drugs now account for approximately 13% of the company’s total $2 billion healthcare budget, a dramatic increase from negligible levels just a few years ago.
The bank employs roughly 211,000 people, making this one of the largest corporate commitments to this class of medication. CEO Brian Moynihan described the expenditure as a good investment during an interview with CNBC, signaling that other employers may follow this path as interest in peptide therapies continues to rise.
Moynihan acknowledged that the bank might not see a full financial return on this spending because some staff members could leave before long-term health savings materialize. Evaluating workforce health remains difficult because outcomes like reduced cardiovascular events or slower chronic disease progression take years to measure and are hard to quantify in standard financial models.
Employers must balance immediate drug costs against broader impacts such as absenteeism, retention, and employee trust. Bank of America uses its size to negotiate lower prices with drugmakers and pharmacy benefit managers, absorbing the uncertainty of the return on investment. This strategy requires a longer timeline than typical annual benefits cycles allow.
The bank supports medication access with health coaching focused on lifestyle changes. Research indicates that GLP-1 use often reduces lean muscle mass alongside fat, though physical function usually remains intact. No clear evidence links these drugs to clinically significant muscle wasting, but risk factors include advanced age and low protein intake.
